UA82434C2 - Полигетероциклические соединения и их применение как антагонистов метаботропного рецептора глютаматау, фармацевтическая композиция на их основе - Google Patents

Полигетероциклические соединения и их применение как антагонистов метаботропного рецептора глютаматау, фармацевтическая композиция на их основе Download PDF

Info

Publication number: UA82434C2
Authority: UA; Ukraine
Prior art keywords: chlorophenyl; methyl; triazol; compound according; group
Prior art date: 2004-02-18

Application number

UAA200608216A

Other languages

English (en)

Ukrainian (uk)

Inventor

Джалай Арора

Луиз Эдвардс

Метвин Айзек

Карин Стааф

Абдельмалик Слесси

Томислав Стефанак

Дейвид Венсбо

Тао Синь

Бьёрн Гольм

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-18

Filing date

2005-02-17

Publication date

2008-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA82434(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-02-17 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-04-10 Publication of UA82434C2 publication Critical patent/UA82434C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UAA200608216A 2004-02-18 2005-02-17 Полигетероциклические соединения и их применение как антагонистов метаботропного рецептора глютаматау, фармацевтическая композиция на их основе UA82434C2 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US54529204P	2004-02-18	2004-02-18
PCT/US2005/005216 WO2005080386A1 (en)	2004-02-18	2005-02-17	Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number	Publication Date
UA82434C2 true UA82434C2 (ru)	2008-04-10

Family

ID=34886130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200608216A UA82434C2 (ru)	2004-02-18	2005-02-17	Полигетероциклические соединения и их применение как антагонистов метаботропного рецептора глютаматау, фармацевтическая композиция на их основе

Country Status (20)

Country	Link
US (2)	US20070185100A1 (ru)
EP (1)	EP1716143A1 (ru)
JP (1)	JP2007523181A (ru)
KR (1)	KR20070052693A (ru)
CN (1)	CN1918154A (ru)
AR (1)	AR047966A1 (ru)
AU (1)	AU2005214378A1 (ru)
BR (1)	BRPI0507481A (ru)
CA (1)	CA2555272A1 (ru)
IL (1)	IL177058A0 (ru)
MX (1)	MXPA06009023A (ru)
NO (1)	NO20063469L (ru)
NZ (1)	NZ548693A (ru)
RU (1)	RU2381226C2 (ru)
SG (1)	SG149900A1 (ru)
TW (1)	TW200538179A (ru)
UA (1)	UA82434C2 (ru)
UY (1)	UY28764A1 (ru)
WO (1)	WO2005080386A1 (ru)
ZA (1)	ZA200606314B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA82434C2 (ru) *	2004-02-18	2008-04-10	Astrazeneca Ab	Полигетероциклические соединения и их применение как антагонистов метаботропного рецептора глютаматау, фармацевтическая композиция на их основе
WO2006048771A1 (en) *	2004-11-04	2006-05-11	Addex Pharmaceuticals Sa	Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
MX2007006695A (es) *	2004-12-03	2007-08-14	Schering Corp	Piperazinas sustituidas como antagonistas de cb1.
JPWO2006080533A1 (ja) *	2005-01-31	2008-06-19	持田製薬株式会社	３−アミノ−１，２，４−トリアゾール誘導体
WO2006123255A2 (en) *	2005-05-18	2006-11-23	Addex Pharma Sa	Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
GB0510142D0 (en) *	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds A1
UY29796A1 (es)	2005-09-29	2007-04-30	Astrazeneca Ab	Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
HUP0500921A2 (en) *	2005-10-05	2007-07-30	Richter Gedeon Nyrt	Tetrazole derivatives, process for their preparation and their use
TW200811157A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators I
TW200808777A (en) *	2006-05-05	2008-02-16	Astrazeneca Ab	MGLUR5 modulators III
TW200811137A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators II
TW200811156A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators IV
US7943622B2 (en)	2006-06-06	2011-05-17	Cornerstone Therapeutics, Inc.	Piperazines, pharmaceutical compositions and methods of use thereof
EP2170846A2 (en) *	2007-06-28	2010-04-07	Intervet International BV	Substituted piperazines as cb1 antagonists
US20100249144A1 (en) *	2007-06-28	2010-09-30	Demong Duane Eugene	Substituted piperazines as cb1 antagonists
MX2010004272A (es)	2007-10-19	2010-04-30	Astrazeneca Ab	Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs).
WO2009054791A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5
WO2009054787A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole carboxylic acid derivatives as modulators of mglur5
WO2009054789A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,3-triazole pyrrolidine derivatives as modulators of mglur5
WO2009054786A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5
WO2009054792A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Aminopyridine derivatives as modulators of mglur5
WO2009054793A1 (en) *	2007-10-26	2009-04-30	Astrazeneca Ab	Thiophene 1,2,4-triazole derivatives as modulators of mglur5
US8546576B2 (en) *	2008-06-06	2013-10-01	Sk Biopharmaceuticals Co., Ltd.	3 or 4-substituted piperidine compounds
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
CA2756989A1 (en) *	2009-04-03	2010-10-07	Douglas Burdi	Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CA2758731A1 (en) *	2009-04-23	2010-10-28	Merck Sharp & Dohme Corp.	2-alkyl piperidine mglur5 receptor modulators
US20120295942A1 (en)	2010-02-01	2012-11-22	Nicholas James Devereux	Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
WO2011092293A2 (en)	2010-02-01	2011-08-04	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh)	2010-02-02	2014-12-24	诺华股份有限公司	用作crf受体拮抗剂的环己基酰胺衍生物
WO2014022752A1 (en)	2012-08-03	2014-02-06	Amgen Inc.	Macrocycles as pim inhibitors
BR112015030824A2 (pt) *	2013-06-11	2017-07-25	Hoffmann La Roche	novos derivados de tetrazolona
BR112020005174A2 (pt) *	2017-09-14	2020-11-10	Daiichi Sankyo Company,Limited	composto que possui estrutura cíclica

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL83275A (en) *	1986-09-08	1994-02-27	Novo Nordisk As	Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
US6660753B2 (en) *	1999-08-19	2003-12-09	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6953805B2 (en) *	2001-01-05	2005-10-11	Eli Lilly And Company	Excitatory amino acid receptor antagonists
CA2462289C (en) *	2001-10-04	2010-02-23	Nicholas D. Cosford	Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
ATE486600T1 (de) *	2002-03-12	2010-11-15	Merck Sharp & Dohme	Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
SE0201943D0 (sv) *	2002-06-20	2002-06-20	Astrazeneca Ab	New use
CA2495179A1 (en) *	2002-08-09	2004-02-19	Astrazeneca Ab	Compounds having an activity at metabotropic glutamate receptors
US7579349B2 (en) *	2003-10-17	2009-08-25	Astrazeneca Ab	4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
GB0325956D0 (en) *	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
UA82434C2 (ru) *	2004-02-18	2008-04-10	Astrazeneca Ab	Полигетероциклические соединения и их применение как антагонистов метаботропного рецептора глютаматау, фармацевтическая композиция на их основе
TW200811157A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators I

2005
- 2005-02-17 UA UAA200608216A patent/UA82434C2/ru unknown
- 2005-02-17 MX MXPA06009023A patent/MXPA06009023A/es active IP Right Grant
- 2005-02-17 EP EP05713792A patent/EP1716143A1/en not_active Withdrawn
- 2005-02-17 RU RU2006127572/04A patent/RU2381226C2/ru not_active IP Right Cessation
- 2005-02-17 CN CNA2005800043398A patent/CN1918154A/zh active Pending
- 2005-02-17 JP JP2006554235A patent/JP2007523181A/ja active Pending
- 2005-02-17 NZ NZ548693A patent/NZ548693A/en unknown
- 2005-02-17 CA CA002555272A patent/CA2555272A1/en not_active Abandoned
- 2005-02-17 BR BRPI0507481-9A patent/BRPI0507481A/pt not_active IP Right Cessation
- 2005-02-17 AU AU2005214378A patent/AU2005214378A1/en not_active Abandoned
- 2005-02-17 US US10/588,754 patent/US20070185100A1/en not_active Abandoned
- 2005-02-17 TW TW094104643A patent/TW200538179A/zh unknown
- 2005-02-17 WO PCT/US2005/005216 patent/WO2005080386A1/en active Application Filing
- 2005-02-17 SG SG200900931-7A patent/SG149900A1/en unknown
- 2005-02-17 KR KR1020067015825A patent/KR20070052693A/ko not_active Application Discontinuation
- 2005-02-18 US US11/060,561 patent/US20060025414A1/en not_active Abandoned
- 2005-02-18 UY UY28764A patent/UY28764A1/es unknown
- 2005-02-18 AR ARP050100612A patent/AR047966A1/es unknown
2006
- 2006-07-25 IL IL177058A patent/IL177058A0/en unknown
- 2006-07-28 ZA ZA200606314A patent/ZA200606314B/xx unknown
- 2006-07-28 NO NO20063469A patent/NO20063469L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
SG149900A1 (en)	2009-02-27
UY28764A1 (es)	2005-06-30
BRPI0507481A (pt)	2007-07-17
NZ548693A (en)	2010-05-28
EP1716143A1 (en)	2006-11-02
AR047966A1 (es)	2006-03-15
KR20070052693A (ko)	2007-05-22
TW200538179A (en)	2005-12-01
ZA200606314B (en)	2007-12-27
US20070185100A1 (en)	2007-08-09
NO20063469L (no)	2006-11-15
AU2005214378A1 (en)	2005-09-01
IL177058A0 (en)	2006-12-10
RU2006127572A (ru)	2008-03-27
CN1918154A (zh)	2007-02-21
WO2005080386A1 (en)	2005-09-01
CA2555272A1 (en)	2005-09-01
JP2007523181A (ja)	2007-08-16
MXPA06009023A (es)	2007-03-08
US20060025414A1 (en)	2006-02-02
RU2381226C2 (ru)	2010-02-10

Publication	Publication Date	Title
UA82434C2 (ru)	2008-04-10	Полигетероциклические соединения и их применение как антагонистов метаботропного рецептора глютаматау, фармацевтическая композиция на их основе
US10683271B2 (en)	2020-06-16	Compositions and methods for modulating farnesoid X receptors
AU2008319308B2 (en)	2013-01-31	P2X3, receptor antagonists for treatment of pain
CN101107243B (zh)	2010-11-24	作为催产素拮抗剂的取代三唑衍生物
CN103842340B (zh)	2017-09-22	核转运调节剂及其应用
CA2599860C (en)	2010-11-23	1, 2, 4-triazole derivatives and their use as oxytocin antagonists
TWI538913B (zh)	2016-06-21	嘌呤衍生物
EP3640247B1 (en)	2022-01-12	Syk inhibitor and use method therefor
TW200843739A (en)	2008-11-16	Novel pyrrolinone derivative and composition containing the same
US20080214622A1 (en)	2008-09-04	Substituted Triazole Derivatives As Oxytocin Antagonists
TW201249828A (en)	2012-12-16	Novel compounds
EP1960391A1 (en)	2008-08-27	Piperazine derivatives and their use in therapy
CA3047002A1 (en)	2018-07-26	Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
CA2539297C (en)	2010-07-20	Substituted triazole derivatives as oxytocin antagonists
AU2005213538A1 (en)	2005-08-25	Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
KR20060123739A (ko)	2006-12-04	나트륨 채널 차단제로서의 치환된 트리아졸
TW201132630A (en)	2011-10-01	Imidazole derivatives
AU2004312342A1 (en)	2005-07-21	5-fluoro-, chloro- and cyano-pyridin-2-yl-tetrazoles as ligands of the metabotropic glutamate receptor-5
UA121046C2 (uk)	2020-03-25	Похідні індолу
RU2360910C2 (ru)	2009-07-10	Производные триазола как ингибиторы 11-бета-гидроксистероиддегидрогеназы-1
UA82435C2 (ru)	2008-04-10	Конденсированные гетероцикличиские соединения и их применение как метаботропных антагонистов рецепторов глутамата, фармацевтическая композиция на их основе
ES2364254T3 (es)	2011-08-29	Piperidinilcarbonil pirrolidinas y su uso como agonistas de melanocortina.
WO2020207263A1 (zh)	2020-10-15	苯并咪唑化合物、其制备方法及其用途
OA18375A (en)	2018-10-16	Indole derivatives.